

Carcinomes ORL

Cristian Moldovan

cristian.moldovan@chb.unicancer.fr



Volume 32, Issue 24

August 20, 2014

JOURNAL OF CLINICAL ONCOLOGY

Official Journal of the
American Society of Clinical Oncology

CONTENTS

SPECIAL SERIES: GERIATRIC ONCOLOGY

Special Series Editors: Paul B. Jacobsen, Stuart M. Lichtman, and Arti Hurria

SPECIAL SERIES OVERVIEW



- Etiologie → Comorbidités
- Traitements multimodaux (chirurgie/radiothérapie ,
radio-chimiothérapie) → Toxicités
→ Efficacité
- ELAN




Etiologie → Comorbidités

- Tabac Alcool → ↓ HPV

Étude Bonner : stratification en fonction du statut HPV

● Résultats



Patients (n=182)

RT p16 -	64	31	17	3	0	0
RT p16 +	34	24	20	12	6	0
RT + Ex p16 -	43	21	16	6	2	0
RT + Ex p16 +	41	33	30	21	12	0

Etiologie → Comorbidités

ANTICANCER RESEARCH 34: 5543-5546 (2014)

Impact of Comorbidity on Initial Treatment and Overall Survival in Elderly Head and Neck Cancer Patients

SAURIN CHOKSHI¹, ARMIN GHOBADI¹, MOHAMMED ATHAR¹, SACHIN SHAH² and JONATHAN DOWELL³




Figure 1. Kaplan-Meier analysis of patients with CCI 0-2 and CCI >2.

Traitements multimodaux (chirurgie/radiothérapie , radio-chimiothérapie)

TUMOUR REVIEW

Head and neck cancer in the elderly: An overview on the treatment modalities

Kostas N. Syrigos ^{a,*}, Dimitris Karachalios ^{a,i}, Eleni M. Karapanagiotou ^{a,b,ii},
Christopher M. Nutting ^{b,ii}, Leonidas Manolopoulos ^{c,iii}, Kevin J. Harrington ^{b,ii}




Fig. 2. Individualized treatment plan in elderly with head and neck cancer.

Toxicités


Toxicity	Grade 2		Grade 3		Grade 4	
	No.	%	No.	%	No.	%
Mucositis, radiation related	152	36	235	55	5	1
Radiation dermatitis	208	49	99	23	5	1
Dysphagia, pharyngeal, radiation related	127	30	239	56	8	2
Voice changes/stridor/larynx	129	30	41	10	1	< 1
Salivary gland changes	274	64	24	6		
Neutrophils	134	32	78	18	25	6
Platelets	17	4	13	3	2	< 1
Hemoglobin	196	46	21	5	6	1
Febrile neutropenia			29	7	5	1
Infection with grade 3 or 4 neutropenia	7	2	3	1	0	0
Infection	69	16	49	12	8	2
Nausea	115	27	55	13	1	< 1
Vomiting	84	20	56	13		
Diarrhea	25	6	11	3		
Cramping	2	< 1	1	< 1	0	0
Rash/desquamation	11	3	2	< 1		
Fatigue	80	19	40	9	2	< 1
Neuropathy, sensory	2	< 1	1	< 1	1	< 1
Inner ear/hearing	59	14	9	2		
Creatinine	37	9	9	2	2	< 1

Meta analysis

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients


Jean-Pierre Pignon^{a,*}, Aurélie le Maître^a, Emilie Maillard^a, Jean Bourhis^b, on behalf of the MACH-NC Collaborative Group¹

(b) by age




Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

James A Bonner, Paul M Harari, Jordi Giralt, Roger B Cohen, Christopher U Jones, Ranjan K Sur, David Raben, Jose Baselga, Sharon A Spencer, Junming Zhu, Hagop Youssoufian, Eric K Rowinsky, K Kian Ang



Métastatique



No. at Risk

	0	3	6	9	12	15
Chemotherapy	220	103	29	8	3	1
Chemotherapy plus cetuximab	222	138	72	29	12	7



Cancer des VADS des patients âgés de 70 ans et plus



Institut de cancérologie
GUSTAVE ROUSSY
VILLEJUIF - WWW.IR.FR



GORTEC
Groupe Oncologie Radiothérapie
Tête Et Cou
Radiotherapy oncology group for head & neck





PROJET ELAN

ELAN-ONCOVAL

PI : J Guigay / C Mertens pour le Gerico – Promotion : IGR

